Inmedica UAB
- Address
- Santariskiu G. 5, Vilniaus M. Sav., 08406 Kaunas, Lithuania
Cardiovascular Diseases
Inmedica UAB is conducting research focused on cardiovascular disease, including studies on atherosclerotic disease, atrial fibrillation, and heart failure, with the goal of testing new therapies that lower risk of heart attacks, strokes, and cardiovascular death.
- Evaluation of innovative lipid‑lowering treatments
- Comparison of novel anticoagulants for stroke prevention in atrial fibrillation
- Assessment of combination regimens for chronic heart failure
- Investigation of agents that reduce major adverse cardiovascular events
The site partners with local cardiology units to bring cutting‑edge options to patients.
Digestive System Diseases
Clinical work at Inmedica UAB includes trials on ulcerative colitis and related inflammatory bowel conditions, aiming to improve disease control and quality of life through novel therapeutic approaches.
- Testing of targeted biologics for ulcerative colitis
- Evaluation of oral agents that modulate gut inflammation
- Long‑term safety studies of emerging treatments
These studies support better management strategies for patients with chronic digestive disorders.
Immune System Diseases
The site is active in trials addressing autoimmune conditions such as rheumatoid arthritis, systemic lupus erythematosus, and psoriatic arthritis, seeking to assess the efficacy of next‑generation immunomodulators.
- Assessment of JAK inhibitors for rheumatoid arthritis
- Evaluation of new agents for lupus disease activity
- Comparative studies of biologic therapies in psoriatic arthritis
The program aims to expand therapeutic choices for patients with immune‑mediated diseases.
Nutritional and Metabolic Diseases
Research at Inmedica UAB targets metabolic disorders including type 2 diabetes, hypertriglyceridemia, and hypertension, with trials designed to test agents that improve metabolic control and reduce cardiovascular risk.
- Investigation of lipid‑lowering RNA therapies
- Study of combination drugs for diabetes and blood pressure management
- Evaluation of novel treatments for severe hypertriglyceridemia
Findings aim to provide safer, more effective options for metabolic disease patients.
Respiratory Tract Diseases
The centre conducts trials for respiratory conditions such as allergic rhinitis and asthma triggered by house dust mite, focusing on immunotherapy approaches to lessen symptoms and improve lung function.
- Assessment of subcutaneous immunotherapy for dust‑mite allergy
- Evaluation of symptom scores during seasonal exposure
- Safety monitoring of long‑term allergen treatment
These efforts aim to reduce the burden of allergic respiratory disease.
Skin and Connective Tissue Diseases
Inmedica UAB explores therapies for chronic skin conditions like chronic spontaneous urticaria, cold‑induced urticaria, and hidradenitis suppurativa, with trials evaluating efficacy, safety, and patient‑reported outcomes.
- Testing of monoclonal antibodies for chronic urticaria
- Comparison of biosimilar agents for hidradenitis suppurativa
- Evaluation of novel treatments for cold‑induced urticaria
The goal is to provide relief for individuals living with persistent skin disorders.
Virus Diseases
The site participates in vaccine studies targeting viral infections, including influenza and varicella, to assess immunogenicity, safety, and optimal administration routes for different age groups.
- Evaluation of adjuvanted influenza vaccine in seniors
- Assessment of a new chickenpox vaccine in infants
- Comparison of intramuscular versus subcutaneous delivery for varicella vaccine
These trials support public health initiatives for effective viral disease prevention.
Immune System Processes
Studies at Inmedica UAB investigate fundamental immune system processes such as cytokine modulation and B‑cell activity, providing insight into mechanisms underlying autoimmune and inflammatory diseases.
- Analysis of B‑cell targeting agents in Sjögren’s syndrome
- Exploration of cytokine inhibition in systemic inflammation
- Biomarker profiling to predict treatment response
Understanding these processes helps refine future therapeutic strategies.
Reproductive and Urinary Physiological Phenomena
Clinical investigations include contraceptive efficacy studies and interventions aimed at preventing pregnancy, evaluating safety, tolerability, and user satisfaction of novel delivery systems.
- Assessment of vaginal delivery system for contraception
- Comparison of hormonal regimens for cycle control
- Safety monitoring of long‑term contraceptive use
Results will inform choices for reproductive health management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 9 therapeutic areas and 15 of 73 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 72 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
- 1Celldex Therapeutics Inc.2active
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG5trials
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 79 other sites in Lithuania
Therapeutic Area Benchmark — Lithuania
Select a therapeutic area to compare against other sites in Lithuania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Lithuania
Market Share
Country: Lithuania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Inmedica UAB
lock Showing 1 of 32 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Barzolvolimab in Participants with Cold-Induced Urticaria and Symptomatic Dermographism | Celldex Therapeutics Inc. | Phase III | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 73 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Barzolvolimab | 3 | Unknown | 2025-04-04 | 2026-04-20 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.